Table 1. Included studies with quantitative data on MDA coverage rates.
| Intervention | Study [reference] | Study Design (N)a | Country | Outcome Measurement Methods | Integrated Program?b | Coverage related factors discussed? |
|---|---|---|---|---|---|---|
| Combined school- and community-based | Oshish 2011 [14] | Pre-Postc (325,509) | Yemen | Drug distributor registers and projected census data | No | Yes |
| Gabrielli 2006 [15] | Pre-post (3,659,211) | Burkina Faso | School and drug distributer registers and census data | No | Yes | |
| Sesay 2014 [16] | Pre-Post (2,375,539) | Sierra Leone | Drug distributors registers and independent survey | No | No | |
| Dembélé 2012 [17] | Pre-post (3,046,078) | Mali | Drug distributor registers and census data | Yes | Yes | |
| Leslie 2011 [18] | Pre-Post (288,078) | Niger | Aggregated treatment registers and national annual treatment summary | No | No | |
| Community-based | Hopkins 2002 [19] | Pre-post (5,214) | Nigeria | Not reported | Yes | No |
| Anto 2011 [20] | Non-randomized control trial (3,520) | Ghana | Aggregated drug distributor registers | Yes | Yes | |
| Mwinzi 2012 [21] | Pre-post (3,677) | Kenya | Aggregated distributor registers and household surveys | No | Yes | |
| Chami 2015 [22] | Observational (935) | Uganda | Drug distributor registers, post-treatment surveys in villages | No | Yes | |
| School-based | Muhumuza 2013a [23] | Observational (1,010) | Uganda | School-based survey of enrolled SAC | No | Yes |
| Muhumuza 2013b [24] | Pre-post (1,020) | Uganda | School-based survey of enrolled SAC | No | Yes | |
| School-based vs. community-based | Ndyomugyeni 2003 [25] | Non-randomized comparative trial (954) | Uganda | Household survey | Yes | Yes |
| Mafe 2005 [26] | Non-randomized comparative trial (3,827) | Nigeria | Household survey | No | Yes | |
| Massa 2009 [27, 28] | Randomized comparative trial (7,039) | Tanzania | Drug distributor registers | No | Yes |
a N is overall number of targeted SAC in study
b Programs were considered to be “integrated” if they included distribution of drugs other than PZQ and albendazole or mebendazole, such as ivermectin or DEC for onchocerciasis and filariasis.
c Pre-post indicates outcomes were scored based on pre- and post-intervention surveys of a non-randomized trial to improve participation
d Aggregate coverage rates were reported for adult and SAC, together, in these studies